SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form F-1 - Registration statement for certain foreign private issuers:
SEC Accession No. 0001213900-24-072968
Filing Date
2024-08-27
Accepted
2024-08-27 16:01:42
Documents
7

Document Format Files

Seq Description Document Type Size
1 REGISTRATION STATEMENT ea0212393-f1_nlspharma.htm F-1 250816
2 OPINION OF WENGER VIELI AG, SWISS COUNSEL TO NLS PHARMACEUTICS LTD ea021239301ex5-1_nlspharma.htm EX-5.1 25381
3 BINDING TERM SHEET, DATED JULY 28, 2024, BY AND BETWEEN NLS PHARMACEUTICS LTD. A ea021239301ex10-21_nlspharma.htm EX-10.21 49310
4 CONSENT OF PRICEWATERHOUSECOOPERS AG ea021239301ex23-1_nlspharma.htm EX-23.1 1676
5 FILING FEE TABLE ea021239301ex-fee_nlspharma.htm EX-FILING FEES 14471
6 GRAPHIC image_001.jpg GRAPHIC 7516
7 GRAPHIC ex5-1_001.jpg GRAPHIC 7233
  Complete submission text file 0001213900-24-072968.txt   363258
Mailing Address THE CIRCLE 6 8058 ZURICH V8 CH-6370
Business Address THE CIRCLE 6 8058 ZURICH V8 CH-6370 41-41-618-80-00
NLS Pharmaceutics Ltd. (Filer) CIK: 0001783036 (see all company filings)

IRS No.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: F-1 | Act: 33 | File No.: 333-281797 | Film No.: 241248934
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)